PET/CT
PRIMARY TUMORS
Fifty-three patients (25 in the Socazolimab + TP group and 28 in the Placebo + TP group) underwent PET/CT twice before and after neoadjuvant treatment. The mean maximum standardized uptake value (SUVmax) of the primary tumors was 16.4/16.1 (Socazolimab + TP group/Placebo + TP group) before treatment but fell to 4.9/4.4 (Socazolimab + TP group/Placebo + TP group) after neoadjuvant therapy; both of these decreases were significant (